U.S. Pharmaceutical Tariffs (Section 232): Implications & Actions

Proposed Section 232 pharmaceutical tariffs signal a major shift in how branded medicines and APIs are manufactured for the U.S. market. Rather than a short-term trade disruption, this policy introduces a tiered framework that links tariff relief directly to domestic manufacturing commitments. Companies importing branded pharmaceuticals may face baseline tariffs unless they can demonstrate credible onshoring plans, with deeper reductions available through approved U.S. manufacturing roadmaps and pricing agreements.

This evolving environment forces leadership teams to weigh difficult trade-offs: absorbing margin pressure, accelerating supply chain restructuring, or engaging federal stakeholders with evidence-based plans. Success depends on more than intent — it requires detailed visibility into product portfolios, manufacturing footprints, tech transfer timelines, capital investments, workforce planning, and regulatory readiness.

Early action can reduce financial exposure while creating long-term strategic advantage. Organizations that build realistic, government-aligned onshoring strategies now will be better positioned to manage risk, maintain compliance, and strengthen supply chain resilience as policy expectations continue to take shape.

Explore the full analysis to understand what’s required —and how to move from uncertainty to execution.